Renaissance Technologies LLC Cuts Stock Position in Burning Rock Biotech Limited (NASDAQ:BNR)

Renaissance Technologies LLC cut its holdings in Burning Rock Biotech Limited (NASDAQ:BNR) by 90.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,617 shares of the company’s stock after selling 309,083 shares during the quarter. Renaissance Technologies LLC owned 0.33% of Burning Rock Biotech worth $217,000 as of its most recent SEC filing.

Separately, Kynam Capital Management LP increased its stake in shares of Burning Rock Biotech by 10.9% during the first quarter. Kynam Capital Management LP now owns 9,640,914 shares of the company’s stock worth $7,020,000 after purchasing an additional 946,488 shares in the last quarter. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

Burning Rock Biotech Trading Down 1.4 %

Shares of Burning Rock Biotech stock opened at $3.24 on Friday. Burning Rock Biotech Limited has a twelve month low of $2.62 and a twelve month high of $11.70. The firm’s 50-day moving average price is $4.78 and its 200 day moving average price is $6.43. The firm has a market capitalization of $33.18 million, a PE ratio of -0.67 and a beta of 0.13.

Burning Rock Biotech (NASDAQ:BNR) last issued its quarterly earnings results on Thursday, August 22nd. The company reported ($0.14) EPS for the quarter. The firm had revenue of $18.65 million for the quarter. Burning Rock Biotech had a negative return on equity of 74.96% and a negative net margin of 111.25%.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.